Two Sigma Investments LP Has $6.31 Million Stock Holdings in Omnicell, Inc. (NASDAQ:OMCL)

Two Sigma Investments LP grew its stake in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 44.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 141,738 shares of the company's stock after acquiring an additional 43,471 shares during the period. Two Sigma Investments LP owned about 0.31% of Omnicell worth $6,310,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC lifted its position in Omnicell by 51.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 803 shares of the company's stock valued at $35,000 after purchasing an additional 273 shares during the last quarter. Johnson Financial Group Inc. bought a new stake in shares of Omnicell during the 4th quarter worth about $37,000. Van ECK Associates Corp raised its position in shares of Omnicell by 47.0% during the 4th quarter. Van ECK Associates Corp now owns 985 shares of the company's stock worth $44,000 after buying an additional 315 shares in the last quarter. Headlands Technologies LLC bought a new stake in shares of Omnicell during the 4th quarter worth about $53,000. Finally, First Horizon Advisors Inc. raised its position in shares of Omnicell by 36.3% during the 4th quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company's stock worth $59,000 after buying an additional 355 shares in the last quarter. 97.70% of the stock is owned by institutional investors and hedge funds.

Omnicell Trading Up 1.3%

Shares of NASDAQ:OMCL traded up $0.39 during mid-day trading on Friday, hitting $30.22. The stock had a trading volume of 756,716 shares, compared to its average volume of 569,878. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.22 and a current ratio of 1.37. The company has a market cap of $1.42 billion, a PE ratio of 111.93, a P/E/G ratio of 7.53 and a beta of 0.78. The company's 50 day moving average is $30.42 and its 200-day moving average is $38.02. Omnicell, Inc. has a 12-month low of $22.66 and a 12-month high of $55.75.

Omnicell (NASDAQ:OMCL - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $0.26 EPS for the quarter, topping the consensus estimate of $0.16 by $0.10. The business had revenue of $269.67 million during the quarter, compared to analysts' expectations of $260.18 million. Omnicell had a net margin of 1.13% and a return on equity of 3.82%. The firm's quarterly revenue was up 9.5% compared to the same quarter last year. During the same period last year, the company posted $0.03 earnings per share. On average, sell-side analysts predict that Omnicell, Inc. will post 1.09 EPS for the current year.

Analyst Ratings Changes

A number of research firms have commented on OMCL. Wells Fargo & Company restated an "overweight" rating and set a $37.00 price target (up from $35.00) on shares of Omnicell in a research report on Friday, May 23rd. JPMorgan Chase & Co. dropped their price target on shares of Omnicell from $44.00 to $36.00 and set a "neutral" rating on the stock in a research report on Thursday, March 20th. Piper Sandler restated an "overweight" rating on shares of Omnicell in a research report on Friday, May 23rd. Benchmark dropped their price target on shares of Omnicell from $62.00 to $40.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Finally, Wall Street Zen raised shares of Omnicell from a "hold" rating to a "buy" rating in a research note on Tuesday, May 20th. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, Omnicell currently has a consensus rating of "Moderate Buy" and an average price target of $44.83.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.